Use of ursodeoxycholic acid in liver diseases

被引:57
作者
Kumar, D [1 ]
Tandon, RK [1 ]
机构
[1] All India Inst Med Sci, Dept Gastroenterol, New Delhi 110029, India
关键词
bile acid; cholestasis; liver diseases; ursodeoxycholic acid;
D O I
10.1046/j.1440-1746.2001.02376.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ursodeoxycholic acid is currently the only established drug for the treatment of chronic cholestatic liver diseases. It has cytoprotective, anti-apoptotic, membrane stabilizing, anti-oxidative and immunomodulatory effects. Prolonged administration of ursodeoxycholic acid in patients with primary biliary cirrhosis (PBC) is associated with survival benefit and a delaying of liver transplantation. There is evidence that it might even prevent progression of the histologic stage of PBC. It also has a beneficial effect on primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, liver disease associated with cystic fibrosis, chronic graft versus host disease, total parenteral nutrition associated cholestasis and various pediatric cholestatic liver diseases. In the present review the current knowledge about the mechanisms of the action and role of ursodeoxycholic acid in the treatment of various liver diseases has been discussed. (C) 2001 Blackwell Science Asia Pty Ltd.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 162 条
[81]   TAUROURSODEOXYCHOLATE PREVENTS BILIARY PROTEIN EXCRETION INDUCED BY OTHER BILE-SALTS IN THE RAT [J].
KITANI, K ;
OHTA, M ;
KANAI, S .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 248 (04) :G407-G417
[82]   MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF AN ORGANIC ANION TRANSPORTING POLYPEPTIDE CLONED FROM HUMAN LIVER [J].
KULLAKUBLICK, GA ;
HAGENBUCH, B ;
STIEGER, B ;
SCHTEINGART, CD ;
HOFMANN, AF ;
WOLKOFF, AW ;
MEIER, PJ .
GASTROENTEROLOGY, 1995, 109 (04) :1274-1282
[83]  
LARKIN JM, 1991, J CELL SCI, V98, P205
[84]  
Laurin J, 1996, HEPATOLOGY, V23, P1464
[85]   Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial [J].
Leuschner, M ;
Maier, KP ;
Schlichting, J ;
Strahl, S ;
Herrmann, G ;
Dahm, HH ;
Ackermann, H ;
Happ, J ;
Leuschner, U .
GASTROENTEROLOGY, 1999, 117 (04) :918-925
[86]   Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis [J].
Leuschner, M ;
Guldutuna, S ;
You, TG ;
Hubner, K ;
Bhatti, S ;
Leuschner, U .
JOURNAL OF HEPATOLOGY, 1996, 25 (01) :49-57
[87]   GALLSTONE DISSOLUTION WITH URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS AND 2 YEARS FOLLOW-UP - A PILOT-STUDY [J].
LEUSCHNER, U ;
LEUSCHNER, M ;
SIERATZKI, J ;
KURTZ, W ;
HUBNER, K .
DIGESTIVE DISEASES AND SCIENCES, 1985, 30 (07) :642-649
[88]   URSODEOXYCHOLIC ACID IN PRIMARY BILIARY-CIRRHOSIS - RESULTS OF A CONTROLLED DOUBLE-BLIND TRIAL [J].
LEUSCHNER, U ;
FISCHER, H ;
KURTZ, W ;
GULDUTUNA, S ;
HUBNER, K ;
HELLSTERN, A ;
GATZEN, M ;
LEUSCHNER, M .
GASTROENTEROLOGY, 1989, 97 (05) :1268-1274
[89]   A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease [J].
Lindblad, A ;
Glaumann, H ;
Strandvik, B .
HEPATOLOGY, 1998, 27 (01) :166-174
[90]   Ursodeoxycholic acid for primary biliary cirrhosis [J].
Lindor, KD ;
Poupon, R ;
Poupon, R ;
Heathcote, EJ ;
Therneau, T .
LANCET, 2000, 355 (9204) :657-658